Cerenome Launches CNSide® CSF Molecular Profile Tests
Cerenome, Inc. announced the commercial launch of CNSide® CSF Molecular Profile tests for comprehensive DNA and RNA profiling of central nervous system cancers using cerebrospinal fluid. These new tests expand diagnostic capabilities beyond leptomeningeal metastases to include primary CNS tumors and hematologic malignancies, offering clinicians act…